In this scientific poster, we describe the development of the Pin-point base editing platform™ to be a versatile base editing technology with broad Cas enzyme and deaminase compatibility well suited for cell and gene therapy.

Read how we have significantly improved the design and delivery parameters of the Pin-point editing machinery, tailoring it for application to disease-relevant cell types. Because many pathogenic SNVs remain unreachable with currently published base editing systems, we looked to further expand the target accessibility by optimizing different components of the system.

Through use of alternate deaminases and Cas enzymes with differing PAM preferences, the Pin-point system can now edit sites previously unattainable using an nCas9-based configuration. We also show how we are further characterizing these novel Pin-point system configurations in the context of therapeutic pipeline development.

Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.